Skip to main content
PLOS One logoLink to PLOS One
. 2022 Nov 21;17(11):e0276465. doi: 10.1371/journal.pone.0276465

Knowledge, attitude, and uptake of human papilloma virus vaccine and associated factors among female preparatory school students in Bahir Dar City, Amhara Region, Ethiopia

Etenesh Adela Lakneh 1,*, Eleni Admassu Mersha 2, Melash Belachew Asresie 2, Habtamu Gebrehana Belay 3
Editor: Kehinde Sharafadeen Okunade4
PMCID: PMC9678319  PMID: 36409675

Abstract

Background

The human papillomavirus vaccine is one of the main preventative measures for cervical cancer. However, global vaccine uptake is low; the problem is particularly acute in low and middle-income countries. The purpose of this study is to assess female preparatory school students’ knowledge, attitude, and uptake of the human papillomavirus vaccine and associated factors in Bahir Dar City, Ethiopia.

Methods

Institutional-based cross-sectional study was conducted among 633 female preparatory school students in Bahir Dar city from March 1–30, 2021. Participants were selected using the multistage sampling technique. Data were collected using a structured self-administered questionnaire and entered into Epi-data and exported to SPSS for analysis. Binary and multivariable logistic regression analyses were done using an odds ratio with a 95% confidence interval. Finally-value < 0.05 was considered significant in multivariable analysis.

Result

The proportion of Human Papillomavirus (HPV) vaccine uptake, knowledge of the vaccine, and respondents’ attitudes toward the vaccine were 45.3% (95% CI = 41.6–49.4%), 58.1% (95% CI = 54.4–61.9%), and 16% (95% CI = 13.2–19.5%), respectively. Having a history of sexual contact AOR = 2.80 (95% CI = 1.64–4.76), hearing about HPV infection AOR = 1.59 (95% CI = 1.13–2.24), and having a positive attitude toward HPV vaccine AOR = 1.46 (95% CI = 1.03–2.08) were significantly associated with knowledge about the HPV vaccine. Discussion of reproductive health issues with family AOR = 2.558 (95%CI = 1.800–3.636), and having good knowledge about HPV vaccine AOR = 3.571(95%CI = 2.494–5.113) were associated with a positive attitude toward the HPV vaccine. Good knowledge AOR = 2.36(95%CI = 1.48–3.76) and a positive attitude toward HPV vaccine AOR = 2.87(95%CI = 1.70–4.85) were strongly associated with HPV vaccine utilization.

Conclusion

In this study, there was a very low uptake of HPV vaccination among female students, and only a small proportion of them had good knowledge of the HPV vaccine and a favorable attitude toward the HPV vaccine.

Introduction

Cervical cancer is one of the world’s major public health issues, as well as the most common sexually transmitted infection among women. Over 99% of cervical cancer cases are associated with genital infection with certain human papillomaviruses [1]. Cervical cancer is the second most common female malignant tumours worldwide. The necessary cause of cervical cancer has been identified as persistent infection with high-risk human papillomavirus (HPV) [2]. Cancer is estimated to account for approximately 5.8% of total national mortality in Ethiopia [3]. The most common cancers in Ethiopia’s adult population are breast cancer (30.2%), cervical cancer (13.4%), and colorectal cancer (5.7%) [4].

Human papillomavirus (HPV) is the most common sexually transmitted infection (STI). Approximately 75% of sexually active people are infected with HPV during their lifetime [5]. More than 100 HPV genotypes are known. Of these, at least 13 genotypes are the cause of cervical cancer and genital and pharyngeal cancers. HPV types (16 and 18) are known to cause 70% of cervical cancers. HPV types 16 and 18 can also cause cancer in other parts of the body, including the vulva, vagina, penis, and anus and 90% of cases of genital warts are caused by HPV types 6 and 11 [6, 7]. The vast majority of HPV infections are asymptomatic or sub-clinical, which has contributed to the rapid transmission and spread of the virus [8].

The human papillomavirus vaccine is one of the most effective ways to prevent HPV infections in women who have never been infected with HPV [9]. The HPV vaccine was first developed by the University of Queensland in Australia and the final form was made by Georgetown University medical center, the University of Rochester, and the United States (U.S). national cancer institute [10]. Food and drug agencies approved the first preventive HPV vaccine under the trade name Gardasil, thereby 64 countries nationally implemented HPV immunization programs [11].

One of the primary prevention strategies for HPV infection is vaccination. HPV vaccination can prevent more than 90% of these cancers [8]. Two HPV vaccines (Gardasil and Cervarix) protect against the two strains of HPV types 16 and 18 [12]. The quadrivalent vaccine is also highly efficacious in preventing genital warts, which are caused by infection with HPV type 6 causes anogenital warts and HPV type 11 causes oropharyngeal cancer [13]. Gardasil works by stimulating the immune system to attack HPV types 6, 11, 16, and 18. Once Gardasil is administered, the body’s immune system recognizes the viral proteins in Gardasil as foreign, and develops antibodies against them, thus providing immunity from future infections [14].

The vulnerability of young, sexually active women is recognized and steps are planned in many countries to implement HPV vaccination [15]. The world health organization recommends that the primary target group for HPV vaccination is girls aged 9–14 years and secondary target populations are females aged ≥ 15 years [16].

The HPV vaccine can prevent infection and cancer at an early age before any exposure to the virus. The HPV vaccine is recommended for everyone through the age of 26 years. Vaccination usually begins at 11 or 12 years of age, but can be given as early as 9 years of age. The decision to vaccinate should be individualized and discussed with the health care provider for older than 26 years of age [17]. The Advisory Committee on Immunization Practices now recommends a 2-dose series starting at 11 to 12 years [18]. Vaccinating girls before initiation of sexual activity is an important primary prevention intervention in a comprehensive cervical cancer prevention and control program. Exposure to HPV during adolescence and young adulthood may cause cervical cancer in later years. Because of this, Ethiopia had initially planned to introduce the HPV vaccine through a routine immunization program [19].

Previous research concentrated on cervical cancer screening; however, Ethiopia began using the HPV vaccine school-based method in December 2018. Studies on HPV vaccine awareness, attitudes, and uptake were scarce. As a result, the purpose of this study is to investigate HPV vaccine knowledge, attitude, and uptake and also its associated factors among female students in Bahir Dar, Ethiopia.

Methods and materials

Study area and period

An institutional-based cross-sectional study was conducted in Bahir Dar City among female preparatory school students in the age group of 15–24 years from March 1–30, 2021. Bahir Dar is the capital city of the Amhara region, which is located 565 km away from Addis Ababa, the capital city of Ethiopia. The estimated total population of Bahir Dar City in 2019 was 445,084. Of this population, 222,097 (49.9%) are males and 222,987 (50.1%) are also females. Bahir Dar city had six government and five private preparatory schools.

Population

All female students enrolled in government and private preparatory schools for the 2021 academic year in Bahir Dar city were the source population and those who were selected in those schools during the data collection period were the study population.

Inclusion and exclusion criteria

Female students registered in selected governmental and private preparatory schools in Bahir Dar city were included, while female students who had lived in the city for less than six months and those who were absent during the data collecting period after two separate visits were excluded.

Sample size determination

Considering the absence of previous data on specific study populations, knowledge, attitude, and uptake of HPV vaccination, the maximum sample size of 50% of prevalence was used in the calculation. The following assumptions were made: by considering the proportion of 50%, 95% confidence interval, and 5% margin of error. Using a design effect of 1.5 and a non-response rate of 10%, the total sample size was 633.

Sampling procedure

The multi-stage sampling technique was used to recruit participants for the study. First, preparatory schools were classified into public and private institutions, and then, using a simple random sampling process, three out of six governmental institutions and two out of four private schools were selected. The resulting sample size was then distributed proportionally to the selected schools. The rosters or name lists of students were utilized as a sampling frame to pick study subjects from each grade level. All students were sorted alphabetically. Finally, 633 students were selected using random computer generator software.

Operational definitions

Uptake of HPV vaccine

Refers to participants who had received at least 1 dose of HPV vaccine.

Good knowledge about the HPV vaccine

When participants answered above or equal to the average number of 10 HPV vaccine knowledge questions, they were considered to have good knowledge of the vaccine.

Attitudes toward the HPV vaccine

When participants scored above or equal to the average score of 12 attitude questions, they were considered to have a positive attitude toward the HPV vaccine.

Data collection procedure and techniques

The data was collected by using pretested and structured self-administered questionnaires after reviewing previous literature. The questionnaire was first developed in English and translated to the local language Amharic. Three diploma nurses who are familiar with the local language were recruited as data collectors. Two-degree midwives were assigned as supervisors for the data collectors, and the investigators provided overall supervision.

Data quality control

The training was given to data collectors and supervisors for two days on data collection procedures, the content of the questionnaire, interview techniques, and confidentiality of the information obtained from the respondents regarding the knowledge, attitude, and uptake of HPV vaccine questions. Before conducting the main study, a pretest was carried out on 32(5%) of the sample in school that were not selected for the actual data collection. The principal investigator and supervisor conducted day-to-day on-site supervision during the whole period of data collection. At the end of each day, the questionnaires were reviewed and checked for completeness and accuracy by the supervisor and investigator. Data quality was ensured during collection, entry, and analysis.

Data processing and analysis

Data were cleaned, coded, and entered by using Epi-Data version 4.6 and then exported to SPSS 21 for analysis. Descriptive statistics were carried out and frequency, tables, and graphs were used to present the descriptive results. On bivariable analysis, all independent variables associated with the dependent variable with p≤0.25 were entered into multivariable analysis, then the significant association was identified based on p<0.05 with 95% CI. Model fitness was checked by using Hosmer and Lemeshow goodness of fit.

Ethical approval and consent to participate

Ethical clearance was obtained from the Institutional Review Board of Bahir Dar University College of Medicine and Health Sciences and a supporting letter was obtained from the Bahir Dar town education office. Permission was obtained from each respective Bahir Dar city preparatory school to conduct the study. Furthermore, after providing appropriate information about the study and the right to refuse participation, each respondent provided verbal informed consent and assent. The parents and guardians of the minors verbally consented before the adolescent females were interviewed. Each school head ensured that participants gave their verbal approval. Respondents were informed that all the data obtained from them was kept confidential and anonymous. To ensure confidentiality, the names of respondents were replaced by code numbers.

Result

Socio-demographic characteristics

A total of 633 students were included in the study, with approximately 620 of them correctly answering the questions, yielding a response rate of 98%. The mean age of study participants was 17 years (SD ±1.18). Almost 90% of participants were in the age range of 15–19 years. Three hundred ninety-eight (64.2%) of the participants were in grade 12 and more than two third of participants 482 (67.7%) were orthodox religious followers (Table 1).

Table 1. Socio-demographic characteristics of female preparatory school students in Bahir Dar city, Ethiopia, 2021(n = 620).

Variables Category Frequency Percent
Age 15–19 555 89.5%
20–24 65 10.5%
Religion Orthodox 482 67.7%
Muslim 79 12.7%
Catholic 32 5.2%
Protestant 27 4.4%
Grade level Grade 11 222 35.8%
Grade 12 398 64.2%
Parents educational status Informal education 84 13. 5%
Primary and secondary 349 56.3%
Diploma and above 187 30.2%
Parents occupation House wife 179 29%
Employed 240 39%
Merchant 163 26%
Others 38 6%
Average family monthly income <4000 85 13.7%
4000–7000 336 54.2%
>7000 199 32.1%

Source of information

Out of a total of 620 participants, 257(41.5%) heard HPV vaccine on radio/television, 178(29%) heard from teachers, 128(20.6%) heard from the internet and 126(20%) heard from parents (Fig 1).

Fig 1. Source of information about HPV vaccine, Bahir Dar, Ethiopia, 2021.

Fig 1

Knowledge about HPV vaccine

Overall, 281 (45.3%) female preparatory school students have good knowledge about the HPV vaccine (Fig 2). More than half of respondents 320(51.6%) knew the HPV vaccine prevents HPV infection and more than two third of participants 472(76.1%) knew that the HPV vaccine prevents cervical cancer. More than half of the participants 361(58.2%) knew the HPV vaccine should be given before the first sexual intercourse and 291(46.9%) knew the HPV vaccine can be given to people who have had a sexual history. More than half of the respondents 334(53.9%) knew the recommended age for HPV vaccine vaccination, which is between the ages of 10 and 14 years, but almost two-thirds of participants 399 (64.4%) did not know the recommended dose of HPV vaccine (Table 2).

Fig 2. Knowledge of respondents about HPV vaccine, Bahir Dar, Ethiopia, 2021.

Fig 2

Table 2. Knowledge toward HPV vaccination among female preparatory school students, Bahir Dar, Ethiopia, 2021(n = 620).

Knowledge items Category Frequency %
Does human papilloma virus vaccine prevent human papilloma virus infection? Yes 320 51.6%
No 300 48.4%
Does human papilloma virus vaccine prevent cervical cancer? Yes 472 76.1%
No 148 23.9%
Is the human papillomavirus vaccine used to prevent genital warts? Yes 320 51.6%
No 300 48.4%
Should a human papilloma virus vaccine be given prior to the first sexual intercourse? Yes 361 58.2%
No 259 41.8%
Can human papilloma virus vaccine be given to people who have had sex? Yes 291 46.9%
No 329 53.1%
Can human papillomavirus vaccine be given to a woman who is already infected with HPV? Yes 285 46.0%
No 335 54.0%
What age range is recommended for vaccination against human papillomavirus infection? 10-14years 334 53.9%
No 286 46.1%
How many doses are recommended for a human papillomavirus vaccine? Two does 221 35.6%
No 399 64.4%
Did you know the schedule for a human papillomavirus vaccination? 6 month-1year 217 35.0%
No 403 65.0%
Did you know the site of vaccine for HPV vaccination? Arm 195 31.5%
No 425 68.5%

Attitude towards HPV vaccine

The overall positive attitude toward the HPV vaccine among respondents was 360 (58%). More than three-fourth of the respondents 478(77%) agree that the HPV vaccine is effective in preventing cervical cancer, and more than two third of respondents 408(65.8%) agree that they will take the vaccine because they believe they are at risk of getting HPV infection, while 392(63.2%) believe that the vaccine’s side effects will not deter them from taking the vaccine. Nearly three-quarters of participants 440(71%) agreed that getting the HPV vaccine before becoming sexually active is preferable, and 472(76%) believe that more information about HPV and its vaccine is needed before getting the vaccine (Table 3).

Table 3. Attitude toward HPV vaccination among female preparatory school students, Bahir Dar, Ethiopia, 2021(n = 620).

Attitude items Agree Disagree Undecided
n (%) n (%) n (%)
HPV vaccine is effective in preventing cervical cancer 478(77) 75(12.1) 67(10.8)
I will take the vaccine because I feel at risk of getting HPV infection 408(65.8) 100(16.1) 112(18.1)
Person who has only one sexual partner can protect from HPV infection 378(61) 79(15.7) 146(32.5)
It’s not necessary to get the human papilloma virus vaccination 177(23.8) 304(49) 94(15.2)
I believe the vaccine’s side effects are reasonable and will not prevent me from receiving the vaccine 392(63.2) 97(15.7) 131(21.1)
I feel it is better to be vaccinated before becoming sexually active 440(71) 59(9.5) 121(19.5)
More information on HPV and its vaccine will be needed before I take the vaccine. 472(76) 47(8) 101(16)
Human papilloma virus vaccine may have long negative effect 294(47.4( 159(25.7) 157(26.9)
I feel only sexually active ladies should get the vaccine 238(38.4) 236(38) 146(23.6)
Do you think your family allow to vaccinate 254(41) 202(32.6) 164(26.4)
Education on HPV vaccine should be implemented at school 469(75.7) 72(11.6) 79(12.7)
HPV vaccination should be included on the National Program on immunization. 462(74.5) 71(11.5) 87(14)

Uptake of HPV vaccine

Only 102 (16%) of respondents had received the HPV vaccine, with one-thirds (33%) having completed the vaccine doses (Fig 3). Of the total participants, 518 (84%) were not vaccinated against HPV in the study area. The main reason for not receiving the HPV vaccine was not being informed by the health care providers 79(15.3%), a lack of knowledge about the vaccine’s safety 270(52%), don’t know where the vaccine is obtained 93(18%), and a lack of parental support 76(14.7%).

Fig 3. Uptake of HPV vaccine among female preparatory school students, Bahir Dra, Ethiopia, 2021.

Fig 3

Factors associated with knowledge of the human papillomavirus vaccination

Multivariable logistic regression revealed that having a history of sexual contact, hearing about HPV infection, and having a positive attitude toward the HPV vaccine were all significantly associated with knowledge about the HPV vaccine. Students who have had a history of sexual contact increased almost 3 times the odds of knowledge about the HPV vaccine as compared to their counterparts [AOR = 2.8, 95% CI = (1.64–4.76)]. Participants who had heard about HPV infection were 1.6 times more likely to have increased knowledge about the HPV vaccine than those who had not heard about HPV infection [AOR = 1.59. 95% CI = (1.13–2.24)]. Participants with a positive attitude toward the HPV vaccine were 1.46 times more likely to increase their knowledge about the HPV vaccine than those with a negative attitude toward the HPV vaccine. [AOR = 1.46, 95%CI = (1.03–2.08] (Table 4).

Table 4. Factors associated with knowledge about HPV vaccine among female preparatory school students, Bahir Dar, Ethiopia, 2021.

Variables Knowledge about HPV vaccination COR (95% CI) AOR (95%CI)
Good Poor
Had ever sexual contact history
Yes 93 45 3.23(2.17–4.82) 2.80(1.64–4.76)
No 188 284 1 1
Heard about HPV infection
Yes 160 155 1.57(1.14–2.16) 1.59(1.13–2.24)
No 121 184 1 1
Attitude about HPV vaccine
Positive attitude 178 182 1.49(1.08–2.05) 1.46(1.03–2.08)
Negative attitude 103 157 1 1

Factors associated with attitudes toward the human papillomavirus vaccination

Participants who discussed reproductive health issues with their partners were nearly three times more likely to favor the HPV vaccine [AOR = 2.56,95% CI = (1.80–3.64)]. Students who were well-informed about the HPV vaccine had nearly four times the positive attitude toward the HPV vaccine [AOR = 3.57, 95% CI = (2.49–5.11)] (Table 5).

Table 5. Factors associated with attitude about HPV vaccination among female preparatory school students, Bahir Dar, Ethiopia, 2021.

Variables Attitude towards HPV vaccine COR (95%CI) AOR (95%CI)
Positive Attitude Poor Attitude
Discussion of RH issues with family
Yes 147 78 3.22(2.25–4.62) 2.56(1.80–3.64)
No 213 182 1 1
Knowledge about HPV Vaccine
Good knowledge 210 71 3.73(2.62–5.26) 3.57(2.49–5.11)
Poor knowledge 150 189 1 1

Factors associated with uptake of human papillomavirus vaccination

Participants with good knowledge of the HPV vaccine were 2.36 times more likely to receive the HPV vaccine than those who had poor knowledge [AOR = 2.36, 95% CI = (1.48–3.76)]. Students with a favorable attitude toward the HPV vaccine were nearly three times more likely to the uptake of HPV vaccine [AOR = 2.87, 95% CI = (1.70–4.85)] (Table 6).

Table 6. Factors associated with uptake of HPV vaccine among female preparatory school students, Bahir Dar, Ethiopia, 2021.

Variables Uptake of HPV vaccine COR AOR
Yes No
Knowledge about HPV vaccination
Good knowledge 65 216 2.46(1.58–3.82) 2.36(1.48–3.76)
Poor knowledge 37 302 1 1
Attitude about HPV vaccine
Positive attitude 79 281 3.17(1.76–4.76) 2.87(1.70–4.85)
Poor attitude 23 237 1 1

Discussion

The primary goal of this study was to provide insight into the level of HPV vaccine knowledge, attitude, and uptake among school students, as well as to identify potential factors associated with HPV vaccine knowledge, attitude, and uptake.

This study revealed that the knowledge about of HPV vaccine among preparatory female students in the study area was found to be 45.3%. This finding is consistent with the findings of other studies in Debre Markos, Ethiopia(47.6%) [20], Indonesia (44.4%) [21], India (44%) [22]. However, this finding is relatively lower than that of study in Brazil at 51.79% [23], Italy at 56.3% [24], and Malaysia at 50.8% [25]. This study found that 58% of the preparatory female students in the study area had a favorable attitude toward the HPV vaccine. This is consistent with a study conducted in Nigeria, which found 61.8% [26]. However, this result is less than those from India (69%) and Benin-City, Nigeria (61.8%) [27, 28].

This study revealed that only 16% of preparatory female students in Bahir Dar town were vaccinated with the HPV vaccine. This is slightly in line with studies done among female college students in mainland China at 11% [29], Mbale District, Uganda at 14% [30], and 16% of the female college students in Kenya had completed the full recommended two-dose schedule [31]. However, this result is significantly lower than the Ugandan study’s 42.4% [32], Germany’s 53% [33], and the United States’ 62.4% [34]. This could be a result of the different sample sizes, study population, and strategies for the healthcare delivery system.

Teachers and the media (radio, television, and the internet) were the main sources of information about HPV vaccination, followed by parents and medical professionals. This is supported by research from Indonesia [35], Nigeria [36], and Turkey [37].

Students with a history of sexual contact, heard about HPV infection, and a positive attitude toward the HPV vaccine had a significant association with HPV vaccine knowledge. Students who discussed reproductive health issues with their partners and those who had good knowledge about HPV infection were significantly associated with positive attitudes toward HPV vaccination. Participants with good knowledge of the HPV vaccine and a favorable attitude toward the HPV vaccine were significantly associated with HPV vaccine uptake.

Students who have a history of sexual contact are more likely to know about the HPV vaccine by 2.8 times. This is consistent with research conducted in Lagos State, Nigeria [38]. The possible reason might be due to students with a history of sexual activity who may fear STIs, HIV, and pregnancy-related issues. They also may be aware that the probability of getting HPV from sexual contact is high. Students ever heard about the HPV vaccine before the study increased 1.59 times the odds of knowledge of the HPV vaccine. This is in line with a study in Brazil [39]. The possible reason might be due to students who have heard about the HPV vaccine may read about it or ask others about its benefits. This increases their understanding of the HPV vaccine’s disadvantages and side effects.

Students with a positive attitude toward the HPV vaccine increased their chances of knowing about the HPV vaccine by 1.46 times. This is consistence with a study conducted in Debre Markos town [20]. This is might be due to the fact that individuals who have a positive attitude towards the vaccine may utilize it. Students’ discussion of the reproductive issue with their parents increased the odds of attitude towards the HPV vaccine by 2.56 times. Parents who are transparent about sexuality with their young children have more robust communication, which is crucial for preventing risky sexual activities like early sexual initiation, unwanted pregnancy, and other reproductive health issues.

Having awareness about the HPV vaccine increased the attitude toward vaccination of HPV vaccine by 3.57 times. This is consistent with the study done in Debre Markos town, Ethiopia [20]. Having a satisfactory level of knowledge about the HPV vaccine increased their uptake of vaccination by 2.36 times. This is in line with research conducted in different parts of Ethiopia, including Ambo Town, Addis Ababa Town, and Gondar Town. [4042].

HPV vaccination is influenced by practice factors, such as adequate health information systems that include provider or patient prompts for vaccine administration [43]. Supporting evidence indicates that adolescents are more likely to receive the HPV vaccine before they begin having sex when they are adequately informed about the vaccines and realize that the vaccine is safe, HPV-related diseases are serious, and adolescents are susceptible. [44]. Knowledge of HPV is important in how people think about their sexuality, protection, and prevention [45]. Having a positive attitude towards the HPV vaccine increased the uptake of the HPV vaccine by 2.87 times. This is a consistent study conducted in Benin City, Nigeria [27], and Uganda [46]. This may be explained by the fact that the majority of motivating/initiative factors in adolescents’ practice are generated by their positive attitude.

Conclusion

The respondent’s knowledge of HPV and attitude toward the HPV vaccine was generally poor, and the uptake of the HPV vaccine was very low. Knowledge of the HPV vaccine was significantly associated with a history of sexual contact, hearing about HPV infection, and having a favorable attitude toward the HPV vaccine. Discussion of reproductive health issues with their families, and knowledge of the HPV vaccine, were found to be associated with a favorable attitude toward the HPV vaccine. Good knowledge and a favorable attitude toward the HPV vaccine were strongly associated with HPV vaccine uptake. The main identified barriers to HPV vaccine uptake were not being informed by health care providers, a lack of knowledge about the vaccine’s safety, not knowing where the vaccine is obtained, and a lack of parental support.

Recommendations

We recommend the Ethiopian Ministry of Health conduct mass HPV vaccinations and community sensitizations to foster positive attitudes and ensure consistent vaccine availability at vaccination sites. For ease of access, the government should make an effort to add the HPV vaccine to the National Program on Immunization (NPI) schedule. All stakeholders should collaborate to improve female students’ knowledge and attitudes toward HPV vaccination.

Supporting information

S1 File. English version questionnaire.

(DOCX)

S2 File. SPSS data.

(SAV)

Acknowledgments

We would like to acknowledge Bahirdar University College of Medicine and Health Sciences for their Ethical approval. Our deepest gratitude goes to our participants for their cooperation during the study as well as their permission to publish this article.

Abbreviations

ACIP

Advisory Committee on Immunization Practices

AOR

Adjusted Odd Ratio

CI

Confidence Interval

COR

Crude Odd Ratio

HPV

Human Papilloma Virus

OR

Odds Ratio

Data Availability

HPV.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Okunade K.S., Human papillomavirus and cervical cancer. Journal of Obstetrics and Gynaecology, 2020. 40(5): p. 602–608. doi: 10.1080/01443615.2019.1634030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mattiuzzi C. and Lippi G., Cancer statistics: a comparison between world health organization (WHO) and global burden of disease (GBD). European journal of public health, 2020. 30(5): p. 1026–1027. doi: 10.1093/eurpub/ckz216 [DOI] [PubMed] [Google Scholar]
  • 3.FMoH, E., National Cancer Control Plan 2016–2020. Addis Ababa DISEASE PREVENTION AND CONTROL DIRECTORATE, editor. DIRECTORATE DPAC, 2015.
  • 4.Federal Ministry of Health Ethiopia. National Cancer Control Plan 2016–2020. https://www.iccp-portal.org/sites/default/files/plans/NCCP%20Ethiopia%20Final%20261015.pdf Accessed June 18, 2019.
  • 5.Weaver BA. Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopath Assoc. 2006;106(3 suppl 1):S2–S8. [PubMed] [Google Scholar]
  • 6.World Health Organization. (2011). Human papillomavirus (HPV). World Health Organization. Retrieved 15th February, 2013, http://www.who.int/nuvi/hpv/en/.
  • 7.Organization WH. Human papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire. 2009;84(15):118–31. [PubMed] [Google Scholar]
  • 8.Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Supplement 1(0)):S4–S15. doi: 10.1016/j.vaccine.2005.09.054 [DOI] [PubMed] [Google Scholar]
  • 9.Chan S. S. C., Ng B. H. Y., Lo W. K., Cheung T. H., & Chung T. K. H. (2009). Adolescent girls’ attitudes on human papillomavirus vaccination. Journal of Pediatric and Adolescent Gynecology, 22(2), 85–90. doi: 10.1016/j.jpag.2007.12.007 [DOI] [PubMed] [Google Scholar]
  • 10.Agorastos T., et al., Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine, 2009. 27(52): p. 7270–7281. doi: 10.1016/j.vaccine.2009.09.097 [DOI] [PubMed] [Google Scholar]
  • 11.Mac-Fiberesima G. Cervical Cancer Knowledge and Risk Behaviors Among Students of University of Port Harcourt, Nigeria 2016.
  • 12.Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: Recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep 2007;56:1–24. [PubMed] [Google Scholar]
  • 13.Bruni L., et al., Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. The Lancet Global Health, 2016. 4(7): p. e453–e463. doi: 10.1016/S2214-109X(16)30099-7 [DOI] [PubMed] [Google Scholar]
  • 14.Sockrider M. and Krishnan J.A., How Vaccines Work to Prevent Infections. American Journal of Respiratory and Critical Care Medicine, 2021. 203(6): p. P16–P17. doi: 10.1164/rccm.2021C1 [DOI] [PubMed] [Google Scholar]
  • 15.Chang Y. T., Chen Y. C., Hayter M., & Lin M. L. Menstrual and menarche experience among pubescent female students in Taiwan: Implications for health education and promotion practice. Journal of Clinical Nursing, 18 (14), 2040–2048. 2009. doi: 10.1111/j.1365-2702.2008.02545.x [DOI] [PubMed] [Google Scholar]
  • 16.World Health Organization. Human papillomavirus vaccines:WHO Vaccine-Preventable Diseases Surveillance Standard, 2018.
  • 17.CDC. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. August 29, 2014. [Google Scholar]
  • 18.Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports. 2011 Nov 25;60(RR-7):1–45. [PubMed]
  • 19.Alene T, Atnafu A, Mekonnen ZA, Minyihun A. Acceptance of Human Papillomavirus Vaccination and Associated Factors Among Parents of Daughters in Gondar Town, Northwest Ethiopia. Cancer Management and Research. 2020;12:8519. doi: 10.2147/CMAR.S275038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sinshaw M.T., Berhe S., and Ayele S.G., Knowledge and Attitude Towards Human Papillomavirus Vaccine and Associated Factors Among Mothers Who Have Eligible Daughters in Debre Markos Town, Northwest Ethiopia. Infection and Drug Resistance, 2022. 15: p. 781. doi: 10.2147/IDR.S352440 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Endarti D., et al., Knowledge, perception, and acceptance of HPV vaccination and screening for cervical cancer among women in Yogyakarta Province, Indonesia. Asian Pacific journal of cancer prevention: APJCP, 2018. 19(4): p. 1105. doi: 10.22034/APJCP.2018.19.4.1105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rashid S., Labani S., and Das B.C., Knowledge, awareness and attitude on HPV, HPV vaccine and cervical cancer among the college students in India. PloS one, 2016. 11(11): p. e0166713. doi: 10.1371/journal.pone.0166713 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kops N.L., et al., Knowledge about HPV and vaccination among young adult men and women: Results of a national survey. Papillomavirus Research, 2019. 7: p. 123–128. doi: 10.1016/j.pvr.2019.03.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Trucchi C, Amicizia D, Tafuri S, Sticchi L, Durando P, Costantino C, et al., Assessment of knowledge, attitudes, and propensity towards HPV vaccine of young adult students in Italy. Vaccines. 2020;8(1):1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Jalani F.F.M., et al., Knowledge, attitude and practice of human papillomavirus (HPV) vaccination among secondary school students in rural areas of Negeri Sembilan, Malaysia. International journal of collaborative research on internal medicine & public health, 2016. [Google Scholar]
  • 26.Onowhakpor AO, Omuemu V., Osagie OL, Odili CG. Community medicine and primary health care human papilloma virus vaccination:, knowledge, attitude and uptake among female medical and dental students in a tertiary institution. J Community Med Prim Heal Care. 2016;28:101–08. [Google Scholar]
  • 27.Onowhakpor A., et al., Human Papilloma Virus vaccination: knowledge, attitude and uptake among female medical and dental students in a tertiary institution in Benin-City, Nigeria. Journal of Community Medicine and Primary Health Care, 2016. 28(2): p. 101–108. [Google Scholar]
  • 28.Radhika M. and Ahmed M., Awareness and knowledge of human papilloma virus (HPV) vaccine in prevention of cervical cancer among medical students. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2018. 7(12): p. 5026–5031. [Google Scholar]
  • 29.You D., et al., Human papillomavirus (HPV) vaccine uptake and the willingness to receive the HPV vaccination among female college students in China: a multicenter study. Vaccines, 2020. 8(1): p. 31. doi: 10.3390/vaccines8010031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Nabirye J., et al., Health system factors influencing uptake of Human Papilloma Virus (HPV) vaccine among adolescent girls 9–15 years in Mbale District, Uganda. BMC Public Health, 2020. 20(1): p. 1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Karanja-Chege C.M., HPV vaccination in Kenya: The Challenges faced and Strategies to increase Uptake. Frontiers in Public Health, 2022: p. 204. doi: 10.3389/fpubh.2022.802947 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Katagwa V.N., et al., Acceptability of human papilloma virus vaccination among primary school girls in Minakulu sub-county, northern Uganda. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP), 2014. 23(4): p. 294. doi: 10.1097/CEJ.0000000000000021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Remschmidt C., et al., Knowledge, attitude, and uptake related to human papillomavirus vaccination among young women in Germany recruited via a social media site. Human vaccines & immunotherapeutics, 2014. 10(9): p. 2527–2535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Liu G., Kong L., and Du P., HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US. Papillomavirus Research, 2016. 2: p. 1–8. doi: 10.1016/j.pvr.2015.10.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Khatiwada M, Kartasasmita C, Mediani HS, Delprat C, Van Hal G, Dochez C., Knowledge, Attitude and Acceptability of the Human Papilloma Virus Vaccine and Vaccination Among University Students in Indonesia. Frontiers in Public Health. 2021:607. doi: 10.3389/fpubh.2021.616456 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Makwe CC, A. R., Odeyemi KA., Human papillomavirus (HPV) infection and vaccines: Knowledge, attitude and perception among female students at the University of Lagos, Lagos, Nigeria. J Epidemiol Glob Health. (2012) 2:199–206. doi: 10.1016/j.jegh.2012.11.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Uzunlar Ö, Özyer S, Başer E, Togrul C, Karaca M, Güngör T, A survey on human papillomavirus awareness and acceptance of vaccination among nursing students in a tertiary hospital in Ankara, Turkey. Vaccine. (2013) 31:2191–5. doi: 10.1016/j.vaccine.2013.01.033 [DOI] [PubMed] [Google Scholar]
  • 38.Oluwole EO, Idowu OM, Adejimi AA, Balogun MR, Osanyin GE., Knowledge, attitude and uptake of human papillomavirus vaccination among female undergraduates in Lagos State, Nigeria. J Family Med Prim Care 2019;8:3627–33. doi: 10.4103/jfmpc.jfmpc_520_19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gattegno M.V., et al., A cross-sectional survey of parental attitudes towards Human papillomavirus vaccination exclusion categories in Brazil. BMC International Health and Human Rights, 2019. 19(1): p. 1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Beyen M.W.M., et al., Human papillomavirus vaccination uptake and its associated factors among adolescent school girls in Ambo town, Oromia region, Ethiopia, 2020. PloS one, 2022. 17(7): p. e0271237. doi: 10.1371/journal.pone.0271237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Dereje N, Ashenafi A, Abera A et al., Knowledge and acceptance of HPV vaccination and its associated factors among parents of daughters in Addis Ababa, Ethiopia: a community-based cross-sectional study. Infect Agents Cancer, 2021. 2021: p. 16–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Alene T, Atnafu A., Mekonnen ZA, Minyihun A, Acceptance of Human Papillomavirus Vaccination and Associated Factors Among Parents of Daughters in Gondar Town, Northwest Ethiopia. Cancer Management and Research, 2020. 12. doi: 10.2147/CMAR.S275038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gilkey M.B. and McRee A.-L., Provider communication about HPV vaccination: a systematic review. Human vaccines & immunotherapeutics, 2016. 12(6): p. 1454–1468. doi: 10.1080/21645515.2015.1129090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.SOUSA P, Takiuti A., Baracat EC, Sorpreso IC, de Abreu LC., Knowledge and acceptance of HPV vaccine among adolescents, parents and health professionals: construct development for collection and database composition. Journal of human growth and development. 2018. [Google Scholar]
  • 45.Contreras-González R., et al., Nivel de conocimientos en adolescentes sobre el virus del papiloma humano. Enfermería universitaria, 2017. 14(2): p. 104–110. [Google Scholar]
  • 46.Kisaakye E., et al., Level and factors associated with uptake of human papillomavirus infection vaccine among female adolescents in Lira District, Uganda. Pan African Medical Journal, 2018. 31(1). doi: 10.11604/pamj.2018.31.184.14801 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Kehinde Sharafadeen Okunade

20 Sep 2022

PONE-D-22-21861Knowledge, Attitude, and Uptake of Human Papilloma Virus Vaccine and Associated Factors Among Preparatory School Female Students in Bahir Dar City, Northwest, EthiopiaPLOS ONE

Dear Dr. Belay,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 03 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kehinde Sharafadeen Okunade

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"no specific funding for this work"

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. 

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in your Competing Interests section:  

"authors have declared that no competing interests exist."

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now 

 This information should be included in your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The author needs to review the spelling and tenses in the manuscript. Also, in the result section, the author needs to rewrite it for clarity. I have highlighted and written comments on areas that need attention in the manuscript.

Reviewer #2: 1. bearing in mind the several problems have been identified with the HL test. For example, it doesn’t take overfitting into account and tends to have low power, What informed the choice of Hosmer and Lemeshow goodness of fit in your methodology

2. Is it descriptive or analytical cross sectional study

3. Its an emerging fact that a single-dose Human Papillomavirus (HPV) vaccine delivers solid protection against HPV, the virus that causes cervical cancer, that is comparable to 2-dose schedules, NO MENTION OF IT IN YOUR MANUSCRIPT

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Aloy Okechukwu Ugwu

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-22-21861.pdf

Attachment

Submitted filename: PONE-D-22-21861.pdf

Decision Letter 1

Kehinde Sharafadeen Okunade

7 Oct 2022

Knowledge, Attitude, and Uptake of Human Papilloma Virus Vaccine and Associated Factors Among Female Preparatory School Students in Bahir Dar City, Amhara Region, Ethiopia

PONE-D-22-21861R1

Dear Dr. Belay,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Kehinde Sharafadeen Okunade

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Kehinde Sharafadeen Okunade

8 Nov 2022

PONE-D-22-21861R1

Knowledge, Attitude, and Uptake of Human Papilloma Virus Vaccine and Associated Factors Among Female Preparatory School Students in Bahir Dar City, Amhara Region, Ethiopia

Dear Dr. Belay:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Kehinde Sharafadeen Okunade

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. English version questionnaire.

    (DOCX)

    S2 File. SPSS data.

    (SAV)

    Attachment

    Submitted filename: PONE-D-22-21861.pdf

    Attachment

    Submitted filename: PONE-D-22-21861.pdf

    Attachment

    Submitted filename: Review Comments to the Author-HPV.docx

    Data Availability Statement

    HPV.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES